Is the 23-valent pneumococcal vaccine necessary for children?

Whether the 23-valent pneumococcal vaccine is necessary depends primarily on the individual patient’s health status. Generally, children aged 3 years and older may receive this vaccine.The 23-valent pneumococcal vaccine—also known as the pneumococcal polysaccharide vaccine (PPSV23)—is used for immunoprophylaxis against diseases caused by Streptococcus pneumoniae. Below are specific details regarding whether administration of the 23-valent pneumococcal vaccine is advisable:

The 23-valent pneumococcal vaccine targets 23 distinct serotypes of Streptococcus pneumoniae, providing protection against invasive disease caused by these 23 capsular serotypes—not against 23 different types of pneumonia. Vaccine selection should therefore be based on individual clinical circumstances.

The 23-valent pneumococcal vaccine is classified as a Category II vaccine in China—that is, it is not part of the national immunization program and is not provided free of charge. Thus, individuals with compromised immune function or heightened susceptibility to respiratory infections may consider vaccination if feasible. Children around 2 years of age are particularly susceptible and may benefit from vaccination at this time; protection typically lasts approximately five years.

It is important to note that receiving the 23-valent pneumococcal vaccine does not guarantee complete immunity against pneumonia. Pneumonia can also be caused by numerous other pathogens—including Mycoplasma pneumoniae, Chlamydia pneumoniae, Staphylococcus aureus, and respiratory syncytial virus (RSV)—none of which are covered by this vaccine.

Additionally, the 23-valent pneumococcal vaccine is a polysaccharide vaccine. Children under 2 years of age have immature immune systems and generally fail to mount an effective immune response to pure polysaccharide antigens. Therefore, the 23-valent pneumococcal vaccine is recommended for high-risk individuals aged 2 years and older—including those with sickle cell disease, HIV infection, asplenia, or chronic illnesses—as well as adults aged 50 years and older, who tend to exhibit stronger immunogenicity following polysaccharide vaccination.